Autosomal Recessive Ataxia Due to PEX10 Deficiency

Neurology

Prevalence

0.1 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Autosomal Recessive Ataxia Due to PEX10 Deficiency?

There are 1 clinical trial targeting Autosomal Recessive Ataxia Due to PEX10 Deficiency tracked by BioSniper.

What is the prevalence of Autosomal Recessive Ataxia Due to PEX10 Deficiency?

The estimated prevalence of Autosomal Recessive Ataxia Due to PEX10 Deficiency is approximately 0.1 per 100,000 population.

Deep-dive into Autosomal Recessive Ataxia Due to PEX10 Deficiency

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Autosomal Recessive Ataxia Due to PEX10 Deficiency — Drugs in Development & Clinical Trials | BioSniper